(Q38007115)

English

Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials

scientific article published on 02 May 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

inflammatory bowel diseases

0 references

0 references

Crohn's disease

0 references

systematic review

1 reference

based on heuristic

inferred from title

author name string

Lee Roth

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

John K MacDonald

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

John W D McDonald

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Nilesh Chande

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

2 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Inflammatory Bowel Diseases

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1333-1339

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Sargramostim for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Adding fuel to the fire: GM-CSF for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Sargramostim in patients with Crohn's disease: results of a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2FIBD.22973

21 January 2018

Identifiers

10.1002/IBD.22973

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38007115&oldid=1736990033"